A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Clinical trial NCT03948763 · TERMINATED

Trial details

NCT number: NCT03948763
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Carcinoma, Non-Small-Cell Lung Pancreatic Neoplasms Colorectal Neoplasms

Start date: 2019-06-26
Primary completion: 2022-08-25
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.